Healt


 Paragon Care (ASX:PGC) and the Fundamentals Driving Market Sentiment

Paragon Care (ASX:PGC) and the Fundamentals Driving Market Sentiment

September 23, 2025 05:12 PM AEST| By Sam

Paragon Care (ASX:PGC) highlights long-term growth through reinvestment and stable fundamentals, showing resilience in healthcare despite market fluctuations and reflecting broader trends in the dynamic ASX stock market.

 Neurizon’s ASX Securities Move Sparks Investor Curiosity

Neurizon’s ASX Securities Move Sparks Investor Curiosity

September 23, 2025 02:18 PM AEST| By Sam

Neurizon Therapeutics (ASX:NUZ) advances with new securities quotation on ASX, boosting visibility and capital access while strengthening biotech representation in the evolving Australian equities and broader ASX stock market landscape.

 Bio-Gene (ASX:BGT) Launches Innovative Tick Solution

Bio-Gene (ASX:BGT) Launches Innovative Tick Solution

September 23, 2025 11:46 AM AEST| By Sam

Bio-Gene (ASX:BGT) demonstrates Flavocide’s strong tick control, offering durable, safe solutions for public health and veterinary markets amid rising Lyme disease concerns.

 Algorae Pharma (ASX:1AI) Expands Oncology Reach ANZ

Algorae Pharma (ASX:1AI) Expands Oncology Reach ANZ

September 23, 2025 11:32 AM AEST| By Sam

Algorae Pharmaceuticals (ASX:1AI) partners with Sakar Healthcare to launch five oncology medicines in Australia and New Zealand, complementing ongoing validation trials.

 Is CSL (ASX:CSL) Still Misunderstood in the ASX 200?

Is CSL (ASX:CSL) Still Misunderstood in the ASX 200?

September 22, 2025 05:54 PM AEST| By Sam

CSL Limited (ASX:CSL) faces cautious sentiment despite resilient fundamentals. Strong return on equity and healthcare leadership highlight its enduring role in the ASX 200 and broader Australian market landscape.

 Starpharma, Genentech Partner on DEP Cancer Therapies in ASX 200

Starpharma, Genentech Partner on DEP Cancer Therapies in ASX 200

September 22, 2025 04:25 PM AEST| By Sam

Starpharma (ASX:SPL) partners with Genentech to develop innovative DEP-based cancer therapies, highlighting opportunities in oncology and strengthening presence in the ASX 200 landscape.

 EVE Health (ASX:EVE) Drives Innovation in Women’s Health with Dyspro Launch

EVE Health (ASX:EVE) Drives Innovation in Women’s Health with Dyspro Launch

September 22, 2025 11:52 AM AEST| By Sam

EVE Health (ASX:EVE) launches Dyspro, a cannabinoid-based gummy for menstrual pain, partnering with TeleDocs Clinic for nationwide distribution in Australia.

 CSL Shares: Exploring Healthcare Strength Within the ASX 200

CSL Shares: Exploring Healthcare Strength Within the ASX 200

September 19, 2025 02:29 AM AEST| By Sam

CSL (ASX:CSL) showcases resilience in healthcare, offering stable revenue, ethical appeal, and global growth opportunities. Positioned within the ASX 200, it remains a cornerstone of long-term market strength.

 Hearing Health Matters: How ASX 200 Innovation Shapes Lives

Hearing Health Matters: How ASX 200 Innovation Shapes Lives

September 18, 2025 03:06 PM AEST| By Sam

Global news links untreated hearing loss to broader health issues. ASX-listed companies like Cochlear and Audeara are providing innovative tech solutions that are integrated into everyday devices.

 Proteomics International Gains ISO 15189, Boosts ASX 200 Outlook

Proteomics International Gains ISO 15189, Boosts ASX 200 Outlook

September 18, 2025 03:05 PM AEST| By Sam

Proteomics International (ASX:PIQ) achieves ISO 15189 certification, strengthening its precision diagnostics portfolio and advancing PromarkerEso’s potential in transforming early cancer detection and global healthcare standards.

 Unlocking the Value of ResMed CDI (ASX:RMD) Shares in 2025

Unlocking the Value of ResMed CDI (ASX:RMD) Shares in 2025

September 17, 2025 05:35 PM AEST| By Sam

Explore an in-depth analysis of ResMed CDI (ASX:RMD) shares, their financial health, revenue trends, and role within the ASX 200 for 2025 investors.

 4DMedical Ltd’s Strategic Quotation of New Securities on ASX 200

4DMedical Ltd’s Strategic Quotation of New Securities on ASX 200

September 17, 2025 02:44 PM AEST| By Sam

4DMedical Ltd (ASX:4DX) strengthens its market presence by quoting new securities on ASX, showcasing innovation in respiratory imaging and highlighting healthcare’s growing role in Australia’s evolving stock market landscape.

 Nyrada’s Xolatryp Shows Breakthrough Potential in Brain and Heart Injury

Nyrada’s Xolatryp Shows Breakthrough Potential in Brain and Heart Injury

September 16, 2025 07:50 PM AEST| By Sam

Nyrada (ASX:NYR) advances its drug candidate Xolatryp, showing mitochondrial stabilisation in brain and heart injury, reinforcing biotech innovation within the dynamic ASX stock market.

 CSL Expands Innovation Pathway with Dutch Partnership: ASX 200 Spotlight on Biotech Growth

CSL Expands Innovation Pathway with Dutch Partnership: ASX 200 Spotlight on Biotech Growth

September 16, 2025 03:06 PM AEST| By Sam

CSL (ASX:CSL), Orthocell (ASX:OCC), and Nyrada (ASX:NYR) drive biotech innovation on the ASX through global partnerships, advanced therapies, and medical devices, strengthening Australia’s healthcare sector and global research impact.

 Mystate Limited’s New Securities Quotation

Mystate Limited’s New Securities Quotation

September 16, 2025 01:57 PM AEST| By Sam

Mystate Limited (ASX:MYS) announces quotation of new securities under a dividend plan, strengthening liquidity, deepening shareholder engagement, and highlighting evolving capital management practices within the Australian Securities Exchange landsca...

 CSL Limited (ASX:CSL) Accelerates Blood Coagulation Treatment Development

CSL Limited (ASX:CSL) Accelerates Blood Coagulation Treatment Development

September 16, 2025 01:08 PM AEST| By Sam

CSL Limited (ASX:CSL) partners with VarmX to develop blood coagulation therapy, enhancing its ASX 200 healthcare portfolio, advancing clinical trials, and driving global patient-centric innovation.

 CSL (ASX:CSL) Advances Innovative Blood Treatment: Key Developments Shaping ASX 200 Insights

CSL (ASX:CSL) Advances Innovative Blood Treatment: Key Developments Shaping ASX 200 Insights

September 16, 2025 11:22 AM AEST| By Sam

CSL (ASX:CSL) partners with VarmX to develop innovative blood therapy, reinforcing its ASX 200 presence and demonstrating leadership in global hematology, plasma treatments, and specialized patient care solutions.

 Nova Eye Medical Expands ASX Presence: Exploring Market Momentum

Nova Eye Medical Expands ASX Presence: Exploring Market Momentum

September 15, 2025 02:33 PM AEST| By Sam

Nova Eye Medical (ASX:EYE) enhances its ASX presence by quoting new securities, aligning employee incentives with innovation goals, and reinforcing stakeholder engagement in the evolving Australian stock market landscape.

 Pro Medicus Hits Two-Month Low: What It Means for the Healthcare Sector and the ASX 200

Pro Medicus Hits Two-Month Low: What It Means for the Healthcare Sector and the ASX 200

September 15, 2025 02:17 PM AEST| By Sam

Pro Medicus (ASX:PME) fell to a two-month low, reflecting broader healthcare weakness across the ASX. Sector trends, commodities, and technology highlight shifting dynamics in the Australian share market.

 EVE Health (ASX:EVE) Expands Women’s Health Pipeline with New Scientific Advisory Board

EVE Health (ASX:EVE) Expands Women’s Health Pipeline with New Scientific Advisory Board

September 15, 2025 12:09 PM AEST| By Sam

EVE Health Group (ASX:EVE) bolsters women’s health research with Dr Fiona Cousins on its Scientific Advisory Board, shaping future innovations in reproductive care.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.